Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

Southwest Research Institute (SwRI) collaborated with the U.S. Air Force to ensure fleet safety after a large crack was unexpectedly found near the cockpit of a T-38 Talon. A new study describes how ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized.

Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Shares of 2seventy bio, Inc. TSVT gained 5.26% after the company announced a definitive merger agreement with Bristol Myers ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...